世界の医療・医薬品産業レポート

TOP  >  作用機序別レポート  >  Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - パイプラインレビュー 2018年上半期

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - パイプラインレビュー 2018年上半期
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Pipeline Review, H1 2018

レポートタイトル Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - パイプラインレビュー 2018年上半期
出版社名 Global Markets Direct
発刊日 2018-04-10
体裁 PDF / 111 ページ
シングルユーザ価格 US$ 3,500
レポート分類 作用機序別レポート
地域 グローバル
領域 -
疾患名 -
薬剤名 -
企業名 -
備考 ※ ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※ 本レポートは、英文です。PDF(電子媒体)での納品となります。

レポート概要

このレポートは、世界の主要国における上記の作用機序を標的とした治療薬パイプラインについての詳細な分析、該当作用機序についての包括的な情報、標的とする治療薬、および適応症、開発段階、作用機序(MoA)、投与方法(RoA)や分子タイプについての分析を提供します。
また、開発の歴史、最新のニュース、プレスリリースについても取り上げます。
さらに、開発中、開発中止プロジェクトの治療薬に関わる主要企業の概要も提供します。
また、該当作用機序の治療薬開発に関わる主要企業概要、開発中止プロジェクトの特集などを提供します。


Global Market Direct社のレポートは、20の治療領域および3000もの適応症をカバーした治験薬を特集しています。
本レポートは、Global Market Direct社独自のデータベース、企業/大学ウェブサイト、SEC書類、企業や大学のウェブサイトからのプレゼンテーションやプレスリリース、および業界特有の第三者情報源、自社分析を基にしたデータや情報を盛り込んでいます。


本レポートは、意思決定能力を高め、競争上の優位性を得るための効果的な戦略を立案するのに役立ちます。
ファーストインクラスやベストインクラス製品を作り出すため、新たなターゲットやMOAを特定することにより、R&Dパイプラインを強化します。


注)本レポートの一部のセクションは、該当疾患におけるデータの可用性や妥当性に基づいて、削除または変更される場合があります。

目次

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Overview
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Companies Involved in Therapeutics Development
BeiGene Ltd
BirchBioMed Inc
Bristol-Myers Squibb Co
CanBas Co Ltd
Eli Lilly and Co
Ensemble Therapeutics Corp
F. Hoffmann-La Roche Ltd
Incyte Corp
Innovent Biologics Inc
IO Biotech ApS
iTeos Therapeutics SA
Jiangsu Hengrui Medicine Co Ltd
Kyowa Hakko Kirin Co Ltd
Luye Pharma Group Ltd
Netherlands Translational Research Center BV
NewLink Genetics Corp
Regen BioPharma Inc
Tempest Therapeutics Inc
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Drug Profiles
AI-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BGB-5777 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dCellVax - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DN-016 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DN-1406131 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EOS-200271 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
epacadostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
galanal - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HTI-1090 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
indoximod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IO-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IO-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KHK-2455 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-01013 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3381916 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-7162 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit IDO and TDO for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NLG-802 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotide to Inhibit IDO1 for Pancreatic Ductal Adenocarcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-70099 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit IDO1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Indoleamine 2,3-Dioxygenase for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Indoleamine 2,3-Dioxygenase for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO and TDO for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO for Oncology and Gastrointestinal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO for Solid Tumor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO-1 for Lewis Lung Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO-1 for Pancreatic Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO/TDO for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO1 and DNA for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRX-3217 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TPST-8844 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target PDL1 and IDO for Metastatic Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Dormant Products
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Discontinued Products
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Product Development Milestones
Featured News & Press Releases
Mar 14, 2018: NewLink Genetics Announces Presentation of Abstracts at AACR Annual Meeting
Feb 09, 2018: iTeos Therapeutics Provides Update on its IDO1 Inhibitor EOS200271 at Molecular Medicine Tri-Conference
Jan 08, 2018: NewLink Genetics Outlines 2018 Business Priorities to Support Phase 3 Pivotal Trial of Indoximod Plus PD-1 Inhibitors
Nov 20, 2017: NewLink Genetics Announces the Presentation of Indoximod Data in Phase 1 Study for Children
Nov 13, 2017: IO Biotech Presented Posters on Preclinical Studies of Melanoma Drug Candidate IO102 at SITC Annual Meeting
Oct 30, 2017: NewLink Genetics Announces FDA Orphan-Drug Designation for Indoximod
Oct 12, 2017: IO Biotech Appoints Dr. Eva Ehrnrooth as Chief Medical Officer
Sep 09, 2017: Progression-Free Survival Data from ECHO-202 Trial of Incyte's Epacadostat in Combination with Merck's KEYTRUDA (pembrolizumab) Underscore Durability of Response in Patients with Advanced Melanoma
Sep 07, 2017: Updated Data for Indoximod Plus KEYTRUDA Demonstrate Improvement of Response Rate for Patients with Advanced Melanoma
Aug 30, 2017: New Data for Epacadostat in Combination with KEYTRUDA (pembrolizumab) Demonstrate Durable Responses in Patients with Advanced Melanoma
Jul 28, 2017: NewLink Genetics provides Updates of Indoximod Program
Jul 27, 2017: NewLink Genetics Announces First Patient Dosed in Phase 1 Study of IDO Pathway Inhibitor NLG802
Jul 10, 2017: NewLink Genetics Receives Notice of Allowance from USPTO Covering Indoximod Salts and Prodrugs
Jun 23, 2017: Positive Phase 1b Data for NewLink Genetics’ IDO Pathway Inhibitor, Indoximod, in Combination with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia Presented at the European Hematologic Association Congress in Madrid, Spain
Jun 05, 2017: NewLink Genetics' Indoximod + PROVENGE Results in Statistically Significant Improvement in Radiographic Progression-Free Survival for Patients with Metastatic Castration Resistant Prostate Cancer in Phase 2 Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018

List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1)
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by BeiGene Ltd, H1 2018
Pipeline by BirchBioMed Inc, H1 2018
Pipeline by Bristol-Myers Squibb Co, H1 2018
Pipeline by CanBas Co Ltd, H1 2018
Pipeline by Eli Lilly and Co, H1 2018
Pipeline by Ensemble Therapeutics Corp, H1 2018
Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
Pipeline by Incyte Corp, H1 2018
Pipeline by Innovent Biologics Inc, H1 2018
Pipeline by IO Biotech ApS, H1 2018
Pipeline by iTeos Therapeutics SA, H1 2018
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018
Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2018
Pipeline by Luye Pharma Group Ltd, H1 2018
Pipeline by Netherlands Translational Research Center BV, H1 2018
Pipeline by NewLink Genetics Corp, H1 2018
Pipeline by Regen BioPharma Inc, H1 2018
Pipeline by Tempest Therapeutics Inc, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd..1), H1 2018
Discontinued Products, H1 2018
Loading....